First-line treatment of advanced acral melanoma with the PD-1 inhibitor toripalimab (Loqtorzi) resulted in a small but ...

As someone who's followed the evolution of cancer treatments closely—both personally, having supported loved ones through their battles, and professionally in the pharmaceutical space—I've been ...

Overall survival (OS) as well as progression-free survival (PFS) were superior when immune checkpoint inhibitors of the programmed cell death 1 (PD-1) apoptosis factor were used in cancer patients ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. PHILADELPHIA — A novel therapy targeting human ...

PD-1 checkpoint proteins on T cells (blue) can bind to two different receptors: PD-L1 and PD-L2. There are many ways to climb a mountain. This saying especially rings true in cancer research, where ...

When many cancers advance, spread and reoccur, checkpoint inhibitors can help keep difficult tumors at bay. These antibody-based immunotherapies can restore the body’s ability to recognize and ...

Eli Lilly has officially given up ex-China rights to Innovent Biologics’ Tyvyt, a PD-1 inhibitor that was once billed as a potential low-cost choice in a multibillion-dollar class. The drug was also ...

Patients were intravenously dosed with balstilimab 3 mg/kg once every 2 weeks and zalifrelimab 1 mg/kg once every 6 weeks, for up to 24 months. The primary end point was objective response rate (ORR, ...